Connecticut 2015 Regular Session

Connecticut House Bill HB05271 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1		General Assembly Committee Bill No. 5271
2	2		January Session, 2015 LCO No. 5125
3		-	~~_____HB05271PH____032415___~~_
	3	+	05125HB05271PH_
4	4		Referred to Committee on PUBLIC HEALTH
5	5		Introduced by:
6	6		(PH)
7	7
8	8		General Assembly
9	9
10	10		Committee Bill No. 5271
11	11
12	12		January Session, 2015
13	13
14	14		LCO No. 5125
15	15
16		-	~~_____HB05271PH____032415___~~_
	16	+	05125HB05271PH_
17	17
18	18		Referred to Committee on PUBLIC HEALTH
19	19
20	20		Introduced by:
21	21
22	22		(PH)
23	23
24	24		AN ACT CONCERNING NEWBORN SCREENING AND A PUBLIC EDUCATION PROGRAM FOR GLOBOID CELL LEUKODYSTROPHY.
25	25
26	26		Be it enacted by the Senate and House of Representatives in General Assembly convened:
27	27
28	28		Section 1. Section 19a-55 of the general statutes is repealed and the following is substituted in lieu thereof (Effective January 1, 2016):
29	29
30	30		(a) The administrative officer or other person in charge of each institution caring for newborn infants shall cause to have administered to every such infant in its care an HIV-related test, as defined in section 19a-581, a test for phenylketonuria and other metabolic diseases, hypothyroidism, galactosemia, sickle cell disease, maple syrup urine disease, homocystinuria, biotinidase deficiency, congenital adrenal hyperplasia and such other tests for inborn errors of metabolism as shall be prescribed by the Department of Public Health. The tests shall be administered as soon after birth as is medically appropriate. If the mother has had an HIV-related test pursuant to section 19a-90 or 19a-593, the person responsible for testing under this section may omit an HIV-related test. The Commissioner of Public Health shall (1) administer the newborn screening program, (2) direct persons identified through the screening program to appropriate specialty centers for treatments, consistent with any applicable confidentiality requirements, and (3) set the fees to be charged to institutions to cover all expenses of the comprehensive screening program including testing, tracking and treatment. The fees to be charged pursuant to subdivision (3) of this subsection shall be set at a minimum of fifty-six dollars. The Commissioner of Public Health shall publish a list of all the abnormal conditions for which the department screens newborns under the newborn screening program, which shall include screening for amino acid disorders, organic acid disorders and fatty acid oxidation disorders, including, but not limited to, long-chain 3-hydroxyacyl CoA dehydrogenase (L-CHAD) and medium-chain acyl-CoA dehydrogenase (MCAD).
31	31
32	32		(b) In addition to the testing requirements prescribed in subsection (a) of this section, the administrative officer or other person in charge of each institution caring for newborn infants shall cause to have administered to every such infant in its care, [(1)] a screening test for (1) cystic fibrosis, [(2) a screening test for] (2) severe combined immunodeficiency disease, and [(3) on and after January 1, 2013, a screening test for] (3) critical congenital heart disease. Such screening tests shall be administered as soon after birth as is medically appropriate.
33	33
34	34		(c) On and after the occurrence of the following: (1) The development and validation of a reliable methodology for screening newborns for adrenoleukodystrophy using dried blood spots and quality assurance testing methodology for such test or the approval of a test for adrenoleukodystrophy using dried blood spots by the federal Food and Drug Administration; and (2) the availability of any necessary reagents for such test, the administrative officer or other person in charge of each institution caring for newborn infants shall cause to have administered to every such infant in its care a test for adrenoleukodystrophy.
35	35
36	36		(d) Not later than six months after the date on which the United States Department of Health and Human Services' Discretionary Advisory Committee on Heritable Disorders in Newborns and Children includes globoid cell leukodystrophy in its uniform screening panel, the administrative officer or other person in charge of each institution caring for newborn infants shall cause to have administered to every such infant in its care, within available appropriations, a test for globoid cell leukodystrophy.
37	37
38	38		[(d)] (e) The provisions of this section shall not apply to any infant whose parents object to the test or treatment as being in conflict with their religious tenets and practice. The commissioner shall adopt regulations, in accordance with the provisions of chapter 54, to implement the provisions of this section.
39	39
40	40		Sec. 2. (NEW) (Effective July 1, 2015) (a) The Commissioner of Public Health shall establish, within available appropriations, a public education program to inform pregnant women and women who may become pregnant concerning: (1) The incidence of globoid cell leukodystrophy; (2) birth defects caused by globoid cell leukodystrophy; (3) methods of diagnosing globoid cell leukodystrophy; and (4) methods of treating globoid cell leukodystrophy. The commissioner shall make such information available to child day care centers and group day care homes, licensed in accordance with section 19a-80 of the general statutes, licensed health care providers who provide services to pregnant women and infants, school nurses and other persons providing health education in schools, and other organizations providing services to children in a group setting.
41	41
42	42		(b) The administrative officer or other person in charge of an institution that administers a newborn screening test for globoid cell leukodystrophy in accordance with section 19a-55 of the general statutes, as amended by this act, shall provide the parent of a newborn information obtained from the Commissioner of Public Health concerning birth defects caused by globoid cell leukodystrophy and available methods of treating globoid cell leukodystrophy.
43	43
44	44
45	45
46	46
47	47		This act shall take effect as follows and shall amend the following sections:
48	48		Section 1 January 1, 2016 19a-55
49	49		Sec. 2 July 1, 2015 New section
50	50
51	51		This act shall take effect as follows and shall amend the following sections:
52	52
53	53		Section 1
54	54
55	55		January 1, 2016
56	56
57	57		19a-55
58	58
59	59		Sec. 2
60	60
61	61		July 1, 2015
62	62
63	63		New section
64	64
	65	+	Statement of Purpose:
	66	+
	67	+	To require a screening test for globoid cell leukodystrophy if recommended by the Department of Health Human Services' Discretionary Advisory Committee of Heritable Disorders in Newborns and Children, and provide education regarding globoid cell leukodystrophy.
	68	+
	69	+	[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]
65	70
66	71
67		-	PH Joint Favorable
68	72
69		-	PH
	73	+	Co-Sponsors: REP. COOK, 65th Dist.; REP. RILEY, 46th Dist.
70	74
71		-	Joint Favorable
	75	+	Co-Sponsors:
	76	+
	77	+	REP. COOK, 65th Dist.; REP. RILEY, 46th Dist.
	78	+
	79	+	H.B. 5271